Seagen
A global biotechnology company dedicated to developing revolutionary therapies with real impact.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 17.5x EV/Revenue -69.0x EV/EBITDA | round | |
* | $12.9m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 36 % | 40 % | 137 % | (28 %) | 25 % | 25 % | 35 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (36 %) | (31 %) | 27 % | (44 %) | (32 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (34 %) | (17 %) | 28 % | (43 %) | (31 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 86 % | 78 % | 38 % | 78 % | 69 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Seagen is a biotechnology company that has been operating for 25 years with a primary focus on transforming cancer care. The company operates in the healthcare sector, specifically in the oncology market. Its main clients are patients suffering from various types of cancer, including solid tumors and blood-related cancers. Seagen's business model revolves around the research, development, and commercialization of innovative cancer therapies.
The company is a pioneer in the development of antibody-drug conjugates (ADCs), which are a type of targeted cancer therapy that delivers cytotoxic drugs directly to cancer cells. This approach has the potential to improve the effectiveness of treatment while reducing side effects, offering a significant advancement in cancer care.
Seagen's revenue is generated through the sale of its approved therapies, as well as through partnerships with other healthcare companies. The company also invests heavily in research and development to create a pipeline of new therapies, ensuring its future growth.
Seagen prides itself on its culture of integrity, collaboration, and diversity. Its team comprises scientists, engineers, clinicians, advocates, and innovators all dedicated to making a real difference for people impacted by cancer.
Keywords: Biotechnology, Cancer Care, Antibody-Drug Conjugates, Oncology, Research and Development, Targeted Therapy, Healthcare, Innovation, Collaboration, Patient Advocacy.
Tech stack
Investments by Seagen
Edit
